By: John Marshall
A single gene-editing infusion from Verve Therapeutics permanently disabled the PCSK9 gene in the liver, reducing LDL cholesterol by an average of 62% in patients with inherited high cholesterol, with effects lasting at least six months. The treatment offers a promising one-time alternative to lifelong daily medications.















